XmAb-2513
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


XmAb-2513
Description :
XmAb-2513 is a humanized monoclonal antibody inhibitor targeting CD30. XmAb-2513 has significant anti-proliferative activity and superior antibody-dependent cell-mediated cytotoxicity (ADCC) as well as antibody-dependent cell-mediated phagocytosis (ADCP) . XmAb-2513 can be used for hematologic malignancies like Hodgkin Lymphoma (HL) and Anaplastic Large Cell Lymphoma (ALCL) research[1].UNSPSC :
12352100Target :
TNF ReceptorRelated Pathways :
ApoptosisField of Research :
CancerReferences & Citations :
[1]Lawrence C E, et al. XmAbâ„¢ 2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies[J]. 2007.Shipping Conditions :
Room temperatureScientific Category :
Inhibitory AntibodiesClinical Information :
No Development ReportedIsoform :
TNFRSF8/CD30

